The Sydney 1000 Bowel Cancer Study and Biobank: a 10 year observational study following the treatment pathways and outcomes of 1000 patients recently diagnosed with colorectal cancer (CRC).

The Sydney 1000 CRC Study and Biobank: a prospective, longitudinal, observational, multi-centre cohort study of 1000 sequential patients diagnosed with all stages of colorectal cancer to better understand disease progression, identify novel biomarkers, determine the impact of toxicity on patient quality of life and develop optimised individualised treatment pathways for future patients.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12618000054213

Enrollment

Registered

2018-01-17

Start date

2017-10-11

Completion date

2019-12-31

Last updated

2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of the Sydney 1000 Bowel Cancer Study is to collect a broad range of information from 1000 prospective bowel cancer patients recently diagnosed with any stage of colorectal cancer for up to 10 years. Who is it for? You may be eligible to join this study if you are aged 18 years or over and have a diagnosis of colorectal cancer (any stage). Study details The clinical research program involves the collection of clinical data at pre-defined time points detailing patients’ response to treatment, supplemented with patient reported outcome data collected from questionnaires during active treatment, regular follow-up (usually 5 years) and for the remainder of the study (up to 10 years). This longitudinal clinical data will be correlated with findings from the biological research program that involves the analysis of longitudinally collected biological samples (tumour, blood, and faeces) and experimental results. The resulting Sydney 1000 Bowel Cancer Study Biobank is expected to contain approximately 1,250 tissue specimens and 25,000 blood and faecal specimens from 1000 participant donors by 2029.

Interventions

Participants will be observed from the point of diagnosis, during active treatment, during short-term clinical follow-up and for up to 10 years (or until the study ends in June 2029). Data collection includes biological samples (colorectal tumour and normal tissue, blood and faecal samples), clinical management data from patient's medical records, patient-reported questionnaires (quality of life, side effects of chemotherapy, nutrition, physical activity, anxiety and depression and lifestyle), a

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

• Over the age of 18 years • Diagnosis of colorectal cancer (any stage of cancer) • Willingness to give written informed consent to participate in the study and to comply with the planned procedures for providing biological samples and outcome data.

Exclusion criteria

• Patients with insufficient English to complete the self-reported questionnaires • People unavailable or unwilling to consent to ongoing follow-up.

Outcome results